Memorial Sloan-Kettering’s Bach Balks At Drug Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
Peter Bach slammed the industry over high drug prices and practices such as rebating, which he said confound open debate about drug cost and benefit, during a panel discussion at the BIO CEO & Investor conference.